Design Therapeutics Stock Price, News & Analysis (NASDAQ:DSGN) $2.43 +0.03 (+1.25%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$2.33▼$2.4450-Day Range$1.99▼$2.5152-Week Range$1.94▼$10.72Volume190,346 shsAverage Volume653,398 shsMarket Capitalization$136.08 millionP/E RatioN/ADividend YieldN/APrice Target$5.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Design Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside133.2% Upside$5.67 Price TargetShort InterestBearish9.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$49,350 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.30) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector636th out of 944 stocksPharmaceutical Preparations Industry296th out of 443 stocks 3.0 Analyst's Opinion Consensus RatingDesign Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.67, Design Therapeutics has a forecasted upside of 133.2% from its current price of $2.43.Amount of Analyst CoverageDesign Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.61% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Design Therapeutics has recently increased by 0.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSGN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Design Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for DSGN on MarketBeat in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,350.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders27.80% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.47% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($1.30) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Design Therapeutics Stock (NASDAQ:DSGN)Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.Read More DSGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSGN Stock News HeadlinesDecember 7, 2023 | morningstar.comDesign Therapeutics Inc DSGNNovember 25, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Design Therapeutics StockDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 16, 2023 | markets.businessinsider.comHold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial UncertaintiesNovember 14, 2023 | finance.yahoo.comDesign Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic UpdateNovember 13, 2023 | finance.yahoo.comDesign Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024September 8, 2023 | fool.comDesign Therapeutics (NASDAQ: DSGN)September 7, 2023 | benzinga.comDirector At This Health Care Company Buys $14.00M of StockDecember 9, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 23, 2023 | finance.yahoo.comWhy Shares of Design Therapeutics Are Plummeting on TuesdayAugust 16, 2023 | markets.businessinsider.comWhy Is Design Therapeutics Stock Moving Lower Today?August 15, 2023 | msn.comWedbush cuts Design Therapeutics to neutral, cites ataxia drug setbackAugust 15, 2023 | msn.comMultiple Downgrades Send Design Therapeutics (NASDAQ:DSGN) Down in FlamesAugust 15, 2023 | msn.comRBC Capital cuts Design Therapeutics to sector perform, cites limited catalystsAugust 15, 2023 | markets.businessinsider.comDesign Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further DevelopmentsAugust 15, 2023 | msn.comDesign Therapeutics stock plunges on trial results for neuromuscular disease treatmentAugust 14, 2023 | finance.yahoo.comDesign Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich AtaxiaAugust 14, 2023 | finance.yahoo.comDesign Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial ResultsAugust 4, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)July 19, 2023 | finance.yahoo.comDSGN - Design Therapeutics, Inc.July 6, 2023 | msn.comDesign Therapeutics (DSGN) Price Target Increased by 18.30% to 27.03June 18, 2023 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Design Therapeutics StockJune 18, 2023 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \May 31, 2023 | finance.yahoo.comDesign Therapeutics to Present at the 2023 Jefferies Healthcare ConferenceMay 18, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Design Therapeutics (DSGN)May 12, 2023 | msn.comWedbush Maintains Design Therapeutics (DSGN) Outperform RecommendationMay 12, 2023 | marketwatch.comTypes of Applications Driving Digital Therapeutics Market Growth: An OverviewSee More Headlines Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DSGN CUSIPN/A CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$5.67 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+133.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,310,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.69% Return on Assets-22.66% Debt Debt-to-Equity RatioN/A Current Ratio23.77 Quick Ratio23.77 Sales & Book Value Annual Sales$230,000.00 Price / Sales591.65 Cash FlowN/A Price / Cash FlowN/A Book Value$5.85 per share Price / Book0.42Miscellaneous Outstanding Shares56,000,000Free Float40,433,000Market Cap$136.08 million OptionableNot Optionable Beta1.62 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Pratik Shah Ph.D. (Age 53)Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Comp: $638.46kDr. Sean Jeffries Ph.D. (Age 43)Chief Operating Officer Comp: $572.21kDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerDr. Elizabeth Gordon Ph.D.Senior Vice President of Regulatory AffairsDr. Jae B. Kim FACC (Age 53)M.D., Chief Medical Officer Ms. Dawn GiangiulioControllerMore ExecutivesKey CompetitorsDianthus TherapeuticsNASDAQ:DNTHNkartaNASDAQ:NKTXAnnexonNASDAQ:ANNXNuvectis PharmaNASDAQ:NVCTCue BiopharmaNASDAQ:CUEView All CompetitorsInsiders & InstitutionsGraham Capital Management L.P.Bought 21,850 shares on 11/22/2023Ownership: 0.039%Walleye Capital LLCBought 362,375 shares on 11/21/2023Ownership: 0.667%RTW Investments LPBought 949,955 shares on 11/15/2023Ownership: 4.488%GSA Capital Partners LLPSold 194,619 shares on 11/15/2023Ownership: 0.078%Corton Capital Inc.Bought 9,811 shares on 11/14/2023Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions DSGN Stock Analysis - Frequently Asked Questions Should I buy or sell Design Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last twelve months. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks. What is Design Therapeutics' stock price target for 2024? 7 brokers have issued twelve-month price targets for Design Therapeutics' shares. Their DSGN share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.67 in the next year. This suggests a possible upside of 133.2% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts. How have DSGN shares performed in 2023? Design Therapeutics' stock was trading at $10.26 on January 1st, 2023. Since then, DSGN shares have decreased by 76.3% and is now trading at $2.43. View the best growth stocks for 2023 here. When is Design Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our DSGN earnings forecast. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.14. What ETFs hold Design Therapeutics' stock? ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares Neuroscience and Healthcare ETF (IBRN). When did Design Therapeutics IPO? (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Design Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (4.49%), Principal Financial Group Inc. (1.28%), Walleye Capital LLC (0.67%), Assenagon Asset Management S.A. (0.44%), Prescott Group Capital Management L.L.C. (0.32%) and Charles Schwab Investment Management Inc. (0.31%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:DSGN) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.